1,027 material Form 8-K filings that 835 companies we cover made with the SEC in February 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Carlyle reported unaudited fourth-quarter and full-year 2024 results. Net income attributable to common stockholders was $211 million in Q4 and $1.0 billion for the year, compared with losses in the same periods of 2023. The board also declared a $0.35 quarterly dividend, with a February 21, 2025 record date and a February 28, 2025 payment date.
Q4 2024 net income attributable to common stockholders was $211 million, or $0.57 per diluted share, versus a loss of $692.0 million in Q4 2023.
FY 2024 net income attributable to common stockholders was $1.0 billion, or $2.77 per diluted share, versus a loss of $608.4 million in FY 2023.
Fee Related Earnings were $287 million in Q4 2024, up 13%, and $1.1 billion for FY 2024, up 29%.
Quarterly dividend of $0.35 per share is payable February 28, 2025 to holders of record on February 21, 2025.
Kilroy Realty reported fourth-quarter 2024 revenue of $286.4 million, up from $269.0 million a year earlier, and net income available to common stockholders of $59.5 million, or $0.50 per diluted share, versus $0.40. For the full year, revenue rose to $1,135.6 million, but net income available to common stockholders fell to $211.0 million, or $1.77 per diluted share, from $1.80, and FFO was $4.59 per diluted share versus $4.62. The company expects 2025 Nareit FFO of $3.85 to $4.05 per diluted share.
Q4 2024 FFO was $1.20 per diluted share, up from $1.08 a year earlier; quarterly leasing reached about 708,000 square feet, the highest quarterly volume since Q4 2019
Stabilized portfolio was 82.8% occupied at December 31, 2024, down from 85.0% a year earlier
Full-year 2024 net income available to common stockholders was $1.77 per diluted share versus $1.80 in 2023
2025 guidance: Nareit FFO of $3.85 to $4.05 per diluted share; same store NOI growth of (1.5%) to (3.0%)
Medpace reported fourth-quarter 2024 revenue of $536.6 million, up 7.7%, and GAAP diluted earnings of $3.67 per share, up from $2.46 a year earlier. The board also approved a $600 million increase to the stock repurchase program, and the company forecast 2025 revenue of $2.110 billion to $2.210 billion, growth of 0.0% to 4.8%, for shareholders to weigh against slower new business awards.
Q4 2024 revenue was $536.6 million, up 7.7% from $498.4 million; GAAP net income was $117.0 million.
Q4 2024 net new business awards fell 13.8% to $529.7 million, for a net book-to-bill ratio of 0.99x.
2025 guidance: revenue of $2.110 billion to $2.210 billion and GAAP diluted EPS of $11.93 to $12.69.
On February 6, 2025, the board approved a $600 million increase to the stock repurchase program.
Astera Labs reported preliminary fourth-quarter 2024 revenue of $141.1 million, up 25% from the prior quarter and up 179% from a year earlier, and GAAP net income of $24.7 million, or $0.14 per diluted share. For full-year 2024, revenue was $396.3 million, but the company reported a GAAP net loss of $83.4 million, which included $88.9 million of stock-based compensation tied to its IPO. The company also projected first-quarter 2025 revenue of $151 million to $155 million, which would be above the fourth-quarter level.
Q4 2024 revenue of $141.1 million, up 25% sequentially and up 179% year over year; GAAP net income of $24.7 million, or $0.14 per diluted share
Full-year 2024 revenue of $396.3 million, up 242%; GAAP net loss of $83.4 million, or $0.64 per share
Q1 2025 outlook: revenue of $151 million to $155 million; GAAP diluted EPS of $0.03 to $0.04; non-GAAP diluted EPS of $0.28 to $0.29
Brixmor reported fourth-quarter 2024 net income attributable to the company of $83.4 million, or $0.27 per diluted share, up from $0.24 a year earlier, and full-year net income of $1.11 per diluted share, up from $1.01. It also gave 2025 guidance of Nareit FFO of $2.19 to $2.24 per diluted share, compared with $2.13 for 2024, and same property NOI growth of 3.50% to 4.50%.
Q4 2024 Nareit FFO was $161.4 million, or $0.53 per diluted share, versus $0.51 in Q4 2023; same property NOI rose 4.7%.
Full-year 2024 Nareit FFO was $647.9 million, or $2.13 per diluted share, versus $2.04 in 2023.
2025 guidance: Nareit FFO of $2.19 to $2.24 per diluted share and same property NOI growth of 3.50% to 4.50%.
Board declared a quarterly dividend of $0.2875 per share, payable April 15, 2025 to holders of record on April 2, 2025.
Inspire Medical Systems reported fourth-quarter 2024 revenue of $239.7 million, up 25% from a year earlier, and diluted earnings per share of $1.15 versus $0.49. It also reaffirmed 2025 revenue guidance of $940 million to $955 million and introduced 2025 diluted EPS guidance of $2.10 to $2.20, which gives shareholders a profit target for the year.
Q4 2024 net income was $35.2 million, with diluted EPS of $1.15 versus $0.49 a year earlier
Full-year 2024 revenue was $802.8 million, up 28%, with net income of $53.5 million and diluted EPS of $1.75
2025 revenue guidance of $940 million to $955 million was reaffirmed; diluted EPS guidance of $2.10 to $2.20 was introduced
Q4 2024 gross margin was 85.0%, compared with 85.4% a year earlier
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.